COQ6-Related Steroid-Resistant Nephrotic Syndrome with Sensorineural Deafness (Primary Coenzyme Q10 Deficiency-6, COQ10D6): Comprehensive Research Report

1. Disease Information

Overview. COQ6-related nephrotic syndrome with sensorineural deafness — designated Primary Coenzyme Q10 Deficiency, Type 6 (COQ10D6) — is an ultra-rare, autosomal recessive mitochondrial disorder caused by biallelic loss-of-function variants in COQ6, a gene required for biosynthesis of coenzyme Q10 (ubiquinone). The disease is defined by the combination of infantile-onset steroid-resistant nephrotic syndrome (SRNS) progressing to end-stage renal failure, together with bilateral sensorineural hearing loss; a subset of patients also develop optic atrophy and/or neurological involvement. It is one of the few genetic causes of SRNS that is potentially treatable, since high-dose CoQ10 (or the analogue idebenone) supplementation can, in a genotype-dependent fashion, halt or reverse disease progression (PMC7358665; GeneReviews NBK410087).

Key identifiers: - OMIM Gene: 614647 — COENZYME Q6, MONOOXYGENASE; COQ6 (omim.org/entry/614647) - OMIM Phenotype: #614650 — COENZYME Q10 DEFICIENCY, PRIMARY, 6 (COQ10D6) (omim.org/entry/614650) - Orphanet: ORPHA:280406 — Familial steroid-resistant nephrotic syndrome with sensorineural deafness caused by COQ6 mutations (orpha.net) - Gene location: Chromosome 14q24.3 - Broader disease group: Primary Coenzyme Q10 Deficiency (a mitochondrial respiratory-chain disorder), GeneReviews overview NBK410087 - HGNC:* COQ6 (gene symbol), NM_182480 (reference transcript)

Synonyms: COQ10D6; Primary ubiquinone deficiency-6; COQ6 nephropathy; COQ6 glomerulopathy; SRNS-deafness syndrome (COQ6-related); COQ6-associated Coenzyme Q10 deficiency.

Evidence base: This is a disease characterized almost entirely from aggregated case series and individual case reports in the literature (originally 11–13 patients in the founding 2011 study, with subsequent single-family and small-cohort reports from Turkey, Lebanon, China, Korea, and other populations) rather than large-scale registries or EHR-derived cohorts — reflecting its rarity (fewer than a few dozen molecularly confirmed families reported to date).

2. Etiology

Disease Causal Factor: Monogenic — biallelic (homozygous or compound heterozygous) pathogenic variants in COQ6, disrupting a step of the CoQ10 (ubiquinone) biosynthetic pathway. There is no known environmental, infectious, or purely mechanistic (non-genetic) cause; this is a primary genetic mitochondrial disease.

Genetic risk factors: - Homozygous or compound heterozygous loss-of-function or missense COQ6 variants are causal. - The founding study (Heeringa et al., 2011, J Clin Invest, PMID 21540551) identified six different COQ6 mutations in 13 individuals from 7 families by homozygosity mapping, establishing the SRNS+deafness phenotype. - Reported pathogenic variants across the literature include: p.Gly255Arg, p.Ala353Asp (c.1058C>A), p.Arg360Trp (c.1078C>T), c.804delC (frameshift), p.Trp14Ter (c.41G>A, nonsense), p.Tyr83Ter (c.249C>G, nonsense), p.Gln461Ter (c.1381C>T), c.189_191delGAA (p.Lys64del), p.Arg162Ter (c.484C>T), p.Gln229Pro (c.686A>C), and p.Pro261Leu (c.782C>T). - ClinVar currently lists 307 reported COQ6 variants, of which 32 alleles are classified pathogenic and 12 likely pathogenic (MARRVEL/ClinVar aggregate, accessed via marrvel.org/human/gene/51004). - All missense variants identified in disease cohorts are predicted damaging by PolyPhen2/SIFT; all premature-stop, frameshift, or splice variants are predicted high-confidence loss-of-function (Sci Rep 2017, DOI 10.1038/s41598-017-17564-y). - Possible genetic modifiers: a 2026 review (Wiley MGG 2026, DOI 10.1002/mgg3.70221) notes that among siblings carrying the same COQ6 variant, co-inheritance of a COQ8B p.(Arg174)/p.(His174) polymorphism was associated with differing severity of renal involvement, suggesting COQ8B may act as a phenotypic modifier of COQ6 disease. - No environmental risk factors, occupational exposures, or infectious triggers have been identified — this is a purely Mendelian condition.

Protective factors: None identified beyond therapeutic CoQ10/idebenone supplementation (see Treatment, §12), which is disease-modifying rather than truly "protective" in a population-genetics sense. No protective alleles have been described.

Gene-environment interactions: Not established; the phenotype is driven by the biosynthetic enzyme defect itself, and no environmental modifier of expressivity has been reported.

3. Phenotypes

Renal phenotype (defining feature)

• Steroid-resistant nephrotic syndrome (SRNS): proteinuria at a median age of onset 1.2 years (range 0.2–6.4 years) in the original cohort (PMC7358665, summarizing Heeringa et al. 2011). Median progression to end-stage renal failure (ESRF) at 1.7 years (range 0.4–9.3 years).
• Renal biopsy: focal segmental glomerulosclerosis (FSGS) is the most common histologic finding; diffuse mesangial sclerosis has also been reported.
• Suggested HP terms: HP:0000100 (Nephrotic syndrome), HP:0000097 (Focal segmental glomerulosclerosis), HP:0000093 (Proteinuria), HP:0003774 / HP:0000083 (Stage 5 chronic kidney disease / Renal insufficiency), HP:0000822 (Hypertension, in some patients).

Auditory phenotype (defining feature)

• Bilateral sensorineural hearing loss (SNHL), typically diagnosed between ages 4–6 years in reported cases, though age of onset is variable and it can be congenital in more severe genotypes.
• Suggested HP term: HP:0000407 (Sensorineural hearing impairment).
• A Korean cohort study (PMC9482153) of 12 patients found the response rate to CoQ10 (no further hearing loss or improvement) was 42.9% among 7 patients with >1 year of serial audiograms; genotype strongly predicted response (see §12).

Ophthalmologic phenotype (variable)

• Optic atrophy, papilledema, and progressive visual loss have been reported in a subset of patients (e.g., visual acuity 20/200 at age 17 in one case, improving to 20/25+ after 3 years of idebenone; PMC7358665).
• Suggested HP terms: HP:0000648 (Optic atrophy), HP:0001622 (Premature birth — not typical), HP:0000587 (Bilateral cataracts — not typical here).

Neurological/systemic phenotype (severe/lethal cases only)

• In the most severe (lethal infantile) presentations: severe metabolic acidosis (lactate up to 7.8 mmol/L), seizures, muscle hypotonia, growth retardation, delayed white matter myelination, bifrontal subarachnoid space widening, atrial septal defect, and pulmonary hypertension — death occurring before 6 months of age in the reported family (PMC8802230).
• Suggested HP terms: HP:0001250 (Seizure), HP:0001943 (Hypoglycemia, not directly reported but common in mitochondrial disease), HP:0002151 (Increased serum lactate), HP:0001252 (Hypotonia), HP:0001510 (Growth delay), HP:0006530 (Interstitial pulmonary disease — n/a), HP:0001631 (Atrial septal defect), HP:0002092 (Pulmonary hypertension).

Phenotype variability and severity spectrum

Clinical severity ranges widely: from isolated, slowly progressive SRNS+SNHL surviving into adulthood, to a lethal infantile multisystem mitochondrial disease with cardiac, neurological, and metabolic involvement dying within months. Even siblings sharing the identical COQ6 genotype can show markedly different renal-phenotype severity (ScienceDirect, "Two siblings with variable expressivity of the renal phenotype"), consistent with modifier effects and/or stochastic factors.

Quality of life impact

No disease-specific QoL instrument data were found in the literature searched; QoL burden is inferable from the combination of ESRD (dialysis/transplant dependency), profound hearing loss (often requiring cochlear implantation), and, in some patients, progressive visual impairment — a multisensory and renal-replacement burden concentrated in early childhood.

4. Genetic/Molecular Information

Causal gene: COQ6 (OMIM *614647), chromosome 14q24.3.

Protein: Coenzyme Q6, monooxygenase — a mitochondrial FAD-dependent monooxygenase of the UbiH/COQ6 family. Two isoforms are described: isoform A (468 aa, ~54 kDa, with an N-terminal mitochondrial targeting leader peptide) and isoform B (~51 kDa, lacking the leader peptide). The protein carries three FAD-binding motifs and catalyzes C5-ring hydroxylation in ubiquinone biosynthesis — specifically the conversion of 3-polyprenyl-4-hydroxybenzoic acid to 3-polyprenyl-4,5-dihydroxybenzoic acid (GeneCards/Wikipedia COQ6; PMC4726752, "Substrate Access Channel in the FAD-Dependent Monooxygenase Coq6"). Human COQ6 shares 66% sequence identity with zebrafish Coq6 and 33% with the E. coli ortholog UbiH, indicating deep evolutionary conservation of this biosynthetic step.

Variant classification and types: Reported pathogenic variants span missense (e.g., p.Ala353Asp, p.Arg360Trp, p.Gly255Arg, p.Gln229Pro, p.Pro261Leu), nonsense (p.Trp14Ter, p.Tyr83Ter, p.Gln461Ter, p.Arg162Ter), and small in-frame/frameshift deletions (c.189_191delGAA/p.Lys64del, c.804delC). All are classified via ACMG/AMP criteria on ClinVar (32 pathogenic, 12 likely pathogenic alleles of 307 total reported variants).

Allele frequency: Individually rare (gnomAD-derived global allele frequencies for ubiquinone-pathway pathogenic variants collectively range 4.1×10⁻⁶–1.7×10⁻⁴, combined ≈1.76×10⁻³ across all CoQ-biosynthesis genes; Sci Rep 2017, DOI 10.1038/s41598-017-17564-y). No COQ6-specific founder allele frequency was identified, though clusters of cases have been reported from Turkish, Lebanese, Chinese, and Korean cohorts, suggesting possible regional enrichment of specific alleles without confirmed founder-effect data in the literature reviewed.

Origin: Germline, autosomal recessive — no somatic COQ6 variants are implicated in this disease.

Functional consequences: Loss-of-function (nonsense/frameshift alleles) or hypomorphic/damaging missense variants reduce COQ6 monooxygenase activity, impairing CoQ10 biosynthesis (a "loss of function" mechanism rather than dominant-negative or gain-of-function). Functional impact category: LOSS_OF_FUNCTION (nonsense/frameshift) or PARTIAL_LOSS_OF_FUNCTION (hypomorphic missense with residual, genotype-dependent enzymatic activity — consistent with the graded CoQ10-treatment response by genotype).

Modifier genes: COQ8B polymorphism (p.Arg174/His174) proposed as a phenotype modifier in siblings sharing an identical COQ6 genotype (Wiley MGG 2026 review).

Epigenetic/chromosomal information: No epigenetic regulation or chromosomal-abnormality mechanism has been reported for this disease; it is driven purely by coding-sequence variants in COQ6.

5. Environmental Information

No environmental, lifestyle, or infectious contributing factors have been identified in the literature. This is a monogenic mitochondrial biosynthetic disorder; disease expression is not modulated by toxin exposure, diet (beyond therapeutic CoQ10 supplementation, which is a treatment rather than a preventive environmental factor), or infectious agents. This section is therefore not applicable beyond noting the absence of such associations.

6. Mechanism / Pathophysiology

Causal chain (upstream → downstream):

1. Molecular defect: Biallelic pathogenic COQ6 variants → loss/reduction of COQ6 FAD-dependent monooxygenase activity → failure of the C5-ring hydroxylation step of ubiquinone (CoQ10) biosynthesis.
2. Biochemical consequence: Reduced cellular/tissue CoQ10 levels. GeneReviews (NBK410087) documents "reduced levels of CoQ10 in skeletal muscle" and "reduced activities of complex I+III and II+III of the mitochondrial respiratory chain" in affected patients — since CoQ10 is the mobile electron carrier shuttling electrons from Complexes I and II to Complex III.
3. Mitochondrial dysfunction: Impaired electron transport chain flux → decreased oxidative phosphorylation/ATP generation and, critically, loss of CoQ10's antioxidant function in the inner mitochondrial membrane.
4. Oxidative stress: In podocyte and zebrafish knockdown models, Coq6 deficiency significantly increased reactive oxygen species (ROS), demonstrated by MitoSOX staining (PMC6247592).
5. Cytoskeletal/structural podocyte injury: ROS-driven damage reduces F-actin expression (with irregular distribution) and decreases nephrin expression, compromising the slit-diaphragm/cytoskeletal integrity essential to the glomerular filtration barrier.
6. Apoptosis: Increased active caspase-3 and caspase-9 (intrinsic mitochondrial apoptotic pathway) documented by flow cytometry and western blot in Coq6-knockdown mouse podocyte cell lines (PMC6247592; original JCI paper PMID 21540551).
7. Clinical/histologic outcome — kidney: Podocyte loss and dysfunction manifest as proteinuria/nephrotic syndrome, progressing histologically to FSGS or diffuse mesangial sclerosis and clinically to ESRF.
8. Clinical outcome — cochlea/eye/CNS: Analogous CoQ10-deficiency-driven oxidative/bioenergetic injury is presumed to underlie sensorineural hearing loss (cochlear hair cells are highly energy-dependent) and optic atrophy/neurologic disease in more severe genotypes, though the cochlear and optic mechanisms are less directly modeled experimentally than the podocyte pathway.

Cell types involved: Podocytes (kidney glomerular visceral epithelial cells) are the best-characterized cellular site of injury (Cell Ontology: CL:0000653, podocyte). Cochlear hair cells and the auditory pathway are presumed targets for SNHL; retinal ganglion cells/optic nerve for optic atrophy.

Key pathway/process annotations (suggested GO terms): - GO:0006744 — ubiquinone biosynthetic process (upstream defective pathway) - GO:0016709 — oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, NAD(P)H as one donor and incorporation of one atom of oxygen (COQ6 monooxygenase activity) - GO:0055114 — oxidation-reduction process - GO:0006979 — response to oxidative stress - GO:0006915 — apoptotic process - GO:0030036 — actin cytoskeleton organization (F-actin/podocyte cytoskeletal injury) - GO:0022900 — electron transport chain

Biochemical abnormalities: Reduced tissue CoQ10; reduced mitochondrial respiratory chain complex I+III and II+III activity (measurable in muscle biopsy or cultured fibroblasts) — the biochemical diagnostic correlate of the genetic defect.

Molecular profiling: No large-scale transcriptomic, proteomic, or single-cell datasets specific to human COQ6-deficient kidney/cochlear tissue were identified in this search; mechanistic data derive principally from candidate-gene knockdown studies (siRNA in mouse podocyte cell lines; morpholino knockdown in zebrafish embryos), not from unbiased omics profiling of patient tissue.

7. Anatomical Structures Affected

Organ level: - Primary: Kidney (glomerulus/podocytes) — nephrotic syndrome, FSGS; Inner ear (cochlea) — sensorineural hearing loss. - Secondary: Eye (optic nerve) — optic atrophy in a subset; in severe infantile cases, heart (atrial septal defect, pulmonary hypertension) and central nervous system (seizures, delayed white matter myelination). - Body systems: Renal/urinary system (primary), auditory system (primary), visual system (secondary), cardiovascular and central nervous systems (secondary, severe cases only).

Tissue/cell level: - Glomerular visceral epithelial cells (podocytes), CL:0000653. - Cochlear hair cells / spiral ganglion neurons (inferred target, not directly demonstrated at single-cell resolution in the literature reviewed). - Retinal ganglion cells / optic nerve axons (optic atrophy).

Subcellular level: Mitochondria — specifically the inner mitochondrial membrane, site of CoQ10's electron-shuttling and antioxidant functions (GO Cellular Component: GO:0005743, mitochondrial inner membrane; GO:0005739, mitochondrion).

Localization (UBERON terms, suggested): - UBERON:0001225 — renal glomerulus - UBERON:0002113 — kidney - UBERON:0000959 — cochlea (auditory system) - UBERON:0001784 — optic nerve - UBERON:0000948 — heart (atrial septal defect in severe cases)

Laterality: Renal disease is systemic/bilateral (both kidneys); sensorineural hearing loss and optic atrophy are typically bilateral.

8. Temporal Development

Onset: Congenital-to-infantile in most reported cases. Proteinuria/nephrotic syndrome onset at a median age of 1.2 years (range 0.2–6.4 years); the most severe (lethal) cases present within the first months of life (3–5 months in the reported lethal sibling pair). Sensorineural hearing loss is typically identified in early childhood (age 4–6 years in several reports), though it can be congenital in severe genotypes.

Onset pattern: Generally insidious/subacute for the renal and auditory phenotypes; acute and rapidly fulminant in the lethal infantile multisystem presentations (metabolic acidosis, seizures, cardiac involvement within weeks to months).

Progression: - Renal: progresses from proteinuria → steroid-resistant nephrotic syndrome → FSGS on biopsy → ESRF, with median time to ESRF of 1.7 years (range 0.4–9.3 years) in the original cohort. Progression is not universal or inevitable in all genotypes when CoQ10 treatment is initiated promptly (see Treatment). - Auditory: progressive in genotype-dependent fashion; some genotypes show ongoing threshold deterioration despite treatment (mean shift +24.1 dB in "non-responders"), others remain stable or even improve (mean shift −5.4 dB in "responders") (PMC9482153). - Ophthalmologic: progressive optic atrophy/visual loss reported in adolescence in some patients, partially reversible with idebenone. - Course pattern: Predominantly progressive, though CoQ10/idebenone therapy can achieve durable remission of proteinuria (sustained ≥12 months in one well-documented case, PMC6208703) and stabilization or improvement of hearing/vision in a genotype-dependent subset — making this a rare example of a "modifiable progressive" course among genetic SRNS syndromes. - Duration: Chronic, lifelong for survivors (renal replacement therapy/transplant, hearing aids/cochlear implants); the most severe infantile-onset multisystem form is fatal within the first year of life.

Remission patterns: Treatment-induced remission of nephrotic-range proteinuria has been documented with CoQ10 supplementation (complete remission within 1 month of initiating 30 mg/kg/day CoQ10 in one case, sustained to at least 12-month follow-up; PMC6208703). No spontaneous remission has been reported.

Critical periods: Early diagnosis and prompt initiation of CoQ10/idebenone therapy — ideally before irreversible glomerular scarring, cochlear damage, or optic nerve injury has occurred — is repeatedly emphasized in the literature as the key window for effective intervention ("Early recognition of this genetic SRNS is mandatory since... can be avoided by adequate treatment based on CoQ10 supplement or an analogue," PMC7358665).

9. Inheritance and Population

Epidemiology: COQ10D6 is ultra-rare; only a few dozen molecularly confirmed cases/families have been reported worldwide since the disease was first delineated in 2011. The broader category of primary CoQ10 deficiency (all 10+ causal genes combined) has an estimated overall incidence of <1:100,000 (GeneReviews NBK410087). No disease-specific prevalence/incidence estimate isolated to COQ6 was found; it should be regarded as one of the rarer genetic subtypes within this already-rare disease group.

Inheritance pattern: Autosomal recessive. At-risk siblings of an affected individual have a 25% recurrence risk when both parents are heterozygous carriers; heterozygous carriers are asymptomatic (GeneReviews NBK410087).

Penetrance: Appears fully penetrant for the core renal phenotype among individuals carrying two pathogenic alleles, though severity (age of onset, rate of progression, extrarenal involvement) is highly variable — including divergent severity between siblings sharing the identical genotype, implicating modifier loci (e.g., COQ8B) and/or environmental/stochastic factors.

Expressivity: Markedly variable — spanning isolated, slowly progressive SRNS+SNHL to lethal infantile multisystem mitochondrial disease, even within the same family/genotype.

Genetic anticipation: Not reported/applicable (not a repeat-expansion disorder).

Germline mosaicism: Not specifically documented in the literature reviewed for COQ6.

Founder effects/consanguinity: The original discovery cohort was identified via homozygosity mapping, implying at least some families were consanguineous; case series have originated from Turkish, Lebanese, Chinese, and Korean populations, suggesting the disease is not confined to a single ethnic group, though no single well-characterized founder allele with quantified frequency was identified in this search.

Carrier frequency: Not specifically reported for COQ6 alone; aggregate carrier/allele-frequency data for CoQ-biosynthesis-pathway pathogenic variants collectively (441 carriers identified across genes in gnomAD) yield a combined pathogenic allele frequency of ~1.76×10⁻³ (Sci Rep 2017).

Population demographics: Reported cases span multiple ethnicities (Turkish, Lebanese, Chinese, Korean, and others); no strong sex predilection has been reported (autosomal recessive inheritance predicts equal sex distribution). Age distribution of affected individuals is concentrated in infancy/early childhood at diagnosis, consistent with the disease's early onset.

10. Diagnostics

Laboratory/clinical tests: - Urinalysis for proteinuria (nephrotic-range), serum albumin, creatinine/eGFR for renal function staging. - Serum/plasma lactate (elevated in severe multisystem presentations, e.g., 5.4–7.8 mmol/L in the lethal sibling case). - Renal biopsy with light and electron microscopy: FSGS or diffuse mesangial sclerosis pattern. - Biochemical CoQ10 assay: reduced CoQ10 levels measurable in skeletal muscle biopsy (the gold-standard tissue) or cultured skin fibroblasts; reduced mitochondrial respiratory chain complex I+III and II+III activities support the diagnosis (GeneReviews NBK410087).

Genetic testing: - Molecular genetic testing is the primary diagnostic approach. Recommended strategies per GeneReviews: multigene panels targeting steroid-resistant nephrotic syndrome, mitochondrial disorders, or ataxia gene panels; or exome/genome sequencing for comprehensive assessment, using sequence analysis plus deletion/duplication analysis of COQ6. - Historically, homozygosity mapping was used in consanguineous families to localize the causal locus (original 2011 discovery cohort). - Single-gene COQ6 Sanger sequencing is an option when the phenotype (SRNS + SNHL) is highly suggestive.

Audiological testing: Serial pure-tone audiometry is recommended for surveillance and to monitor treatment response; Categorical Auditory Performance (CAP) scoring is used post-cochlear-implantation.

Ophthalmologic testing: Formal ophthalmologic evaluation (visual acuity, fundoscopy for optic atrophy/papilledema) is recommended, especially in patients on long-term follow-up.

Differential diagnosis: Other genetic causes of SRNS (e.g., NPHS1, NPHS2, WT1, COQ2, COQ8B [note: COQ8B nephropathy is a closely related, better-characterized CoQ-pathway SRNS disorder, also CoQ10-responsive, but classically without deafness]), other mitochondrial CoQ10 deficiency subtypes (COQ2, COQ4, COQ7, COQ8A, COQ8B, COQ9, PDSS1, PDSS2, ADCK3/4), and syndromic deafness-nephropathy conditions (e.g., Alport syndrome — differentiated by lack of hematuria/lens abnormalities typical of Alport, and by biochemical/molecular confirmation of the CoQ pathway defect).

Screening: No population-based newborn or carrier screening program specific to COQ6 was identified; given its rarity, targeted carrier screening would typically only be pursued in families with a known proband or in consanguineous unions with a positive family history.

11. Outcome / Prognosis

Survival/mortality: Highly variable by genotype and treatment timing. Without treatment, the disease inexorably progresses to ESRF (median age 1.7 years in the founding cohort), and the most severe genotypes are lethal in infancy (reported deaths at 4–6 months of age in a compound-heterozygous nonsense-variant sibling pair, PMC8802230). In the original 11-patient cohort referenced by later reports, "five [were] dying in early childhood (median age: 5.0 years)" — indicating substantial early mortality historically, prior to widespread recognition of CoQ10-treatment responsiveness.

Morbidity/function: Survivors face ESRD requiring dialysis and/or renal transplantation, profound bilateral sensorineural hearing loss frequently requiring cochlear implantation, and in some cases progressive visual impairment. No formal QoL instrument data (EQ-5D, SF-36) specific to this condition were found.

Complications: ESRD, hypertension, growth retardation, and — in the most severe multisystem cases — cardiac defects (atrial septal defect, pulmonary hypertension), seizures, and CNS white-matter abnormalities.

Recovery potential with treatment: This is the most distinctive feature of the prognosis — early, appropriately dosed CoQ10 (or idebenone) treatment can produce complete and sustained remission of proteinuria (documented to ≥12 months follow-up), stabilization or improvement in visual acuity (idebenone), and — in a genotype-dependent subset (~43% response rate for stable/improved hearing in one cohort) — preservation of hearing.

Prognostic factors: - Genotype is the dominant prognostic variable. Homozygosity for p.Gly255Arg or p.Ala353Asp was associated with good CoQ10 response (GeneReviews). Conversely, c.686A>C (p.Gln229Pro) was associated with poor audiological response, while c.189_191delGAA and c.782C>T were associated with better audiological outcomes (PMC9482153); a patient homozygous for p.Pro261Leu (c.782C>T) maintained entirely normal hearing throughout follow-up. - Timing of diagnosis/treatment initiation relative to onset of irreversible organ damage is repeatedly cited as critical. - Compound heterozygous truncating (nonsense) variants appear to correlate with the most severe, multisystem, and lethal presentations.

12. Treatment

Pharmacotherapy (targeted, disease-modifying): - Coenzyme Q10 (ubiquinone-10) oral supplementation is the cornerstone treatment. Doses reported in the literature range from 5–50 mg/kg/day (GeneReviews range), with 30 mg/kg/day (in three divided doses) used in several published cohorts/case reports (PMC9482153; PMC6208703; PMC6247592). CHEBI term: CHEBI:46245 (ubiquinone-10 / coenzyme Q10). NCIT treatment-action term: NCIT:C15986 (Pharmacotherapy), with therapeutic_agent = coenzyme Q10 (CHEBI:46245); modality classification: SMALL_MOLECULE (or arguably PROTEIN_REPLACEMENT-adjacent "metabolite replacement," though CoQ10 itself is a lipophilic small molecule). - Idebenone, a hydrophilic short-chain synthetic CoQ10 analogue with improved bioavailability/tissue penetration, has been used successfully particularly for the ophthalmologic (optic atrophy) manifestation, at doses of 10–15 mg/kg/day (PMC7358665). CHEBI term: CHEBI:81816 (idebenone). - Prior to CoQ10/idebenone diagnosis, patients are frequently trialed unsuccessfully on standard nephrotic-syndrome immunosuppression — prednisone/corticosteroids (ineffective, consistent with the "steroid-resistant" designation), ACE inhibitors/ARBs (e.g., ramipril; supportive antiproteinuric effect only), and calcineurin inhibitors (e.g., cyclosporine A, achieving only partial remission in one reported case before CoQ10 achieved complete remission) (PMC6208703; PMC7358665).

Pharmacogenomics: Treatment response to CoQ10/idebenone is strongly genotype-dependent (see §11), representing an emerging genotype-guided precision-medicine approach within this single-gene disease, though no formal CPIC/PharmGKB guideline exists given the disease's rarity.

Renal replacement/surgical: - Renal transplantation (NCIT:C15289, Organ Transplantation) and dialysis/hemodialysis for patients progressing to ESRF despite treatment.

Auditory intervention: - Cochlear implantation for patients with severe/progressive sensorineural hearing loss unresponsive to CoQ10; a case series of 4 implanted patients showed Categorical Auditory Performance (CAP) scores improving from an average of 3.2 preoperatively to 6.7 at final follow-up, sustained over an average 61.9 months (PMC9482153). - Hearing aids for milder hearing loss (inferred standard-of-care, not specifically detailed in sources reviewed).

Supportive care: Nutritional support/growth monitoring (accelerated growth was noted as a positive secondary outcome of successful CoQ10 treatment in one case report, alongside improved dental health and reduced respiratory infections — PMC6208703), blood pressure management, and general chronic kidney disease supportive management.

Experimental/investigational: No COQ6-specific registered clinical trials were identified on ClinicalTrials.gov. General CoQ10-in-CKD trials exist (e.g., NCT03579693, NCT05942027) but target broader chronic kidney disease populations, not the COQ6-specific genetic subtype, and used much higher, non-weight-based adult dosing (1,200 mg/day) without disease-specific benefit in short-term endpoints — underscoring that the genetically targeted, weight-based dosing paradigm used in COQ6 case reports is distinct from generic CoQ10-for-CKD approaches.

Treatment outcomes/adverse events: No significant CoQ10-related adverse events were reported in the case series reviewed; the main "failure mode" is incomplete or absent response in genotypes with more severe loss-of-function variants, and interestingly, one report noted that serum CoQ10 levels remained variable despite consistent dosing and clinical improvement, suggesting the therapeutic effect may act locally at the tissue level rather than being reliably tracked by serum levels (PMC6208703).

Treatment strategy summary: Early genetic diagnosis → immediate high-dose oral CoQ10 (and/or idebenone, particularly if optic involvement) → serial monitoring of proteinuria, audiometry, and visual acuity → escalation to cochlear implantation for non-responsive hearing loss and renal replacement therapy/transplantation for those progressing to ESRF despite treatment.

13. Prevention

Primary prevention: None possible for the genetic defect itself (autosomal recessive Mendelian disease); the only "primary prevention" analog is reproductive genetic counseling and prenatal/preimplantation genetic testing in families with a known proband, given the 25% recurrence risk to future siblings.

Secondary prevention (early detection): This is where intervention is most impactful for this disease — early recognition of the SRNS + SNHL phenotype (or a positive family history) and prompt genetic diagnosis enables initiation of CoQ10/idebenone therapy before irreversible glomerular, cochlear, or optic nerve damage occurs, which the literature repeatedly frames as the key modifiable determinant of outcome.

Genetic counseling: Standard autosomal recessive counseling applies — carrier parents have a 25% risk per pregnancy of an affected child; carrier testing of at-risk relatives and prenatal diagnosis are options once the familial pathogenic variants are known (GeneReviews NBK410087).

Screening: No population-level newborn or carrier screening program specific to COQ6 exists; targeted testing is reserved for families with an identified proband, given the disease's extreme rarity.

Public health/environmental interventions: Not applicable — this is not a disease with an environmental or public-health prevention dimension.

Prophylaxis: Continuous CoQ10 supplementation functions as ongoing secondary/tertiary prophylaxis against further nephron loss, hearing deterioration, and optic nerve injury once diagnosis is established, rather than as a true "primary preventive" measure.

14. Other Species / Natural Disease

No naturally occurring veterinary or wildlife disease caused by Coq6 mutations has been reported in the literature searched (e.g., no OMIA entries or veterinary case series were identified). The Coq6 gene is broadly conserved across vertebrates (mouse ortholog: MGI:1924408; zebrafish ortholog: 66% identity to human COQ6). No zoonotic or cross-species transmission relevance applies, as this is a non-infectious, purely genetic disease.

Comparative biology: The deep evolutionary conservation of the ubiquinone biosynthesis pathway — from the bacterial E. coli ortholog UbiH (33% identity to human COQ6) through zebrafish (66% identity) — underlies why zebrafish and mouse-cell models have proven experimentally tractable despite the absence of documented spontaneous natural disease in non-human species.

15. Model Organisms

Cellular/in vitro models: - Mouse podocyte cell line, siRNA knockdown of Coq6: Decreased cell growth, increased apoptosis (increased caspase-3 and caspase-9 activation), increased ROS (via MitoSOX staining), reduced F-actin expression with cytoskeletal disorganization, and reduced nephrin expression. CoQ10 treatment partially reversed the apoptotic phenotype in knockdown podocytes (PMID 21540551; PMC6247592). Notably, exogenously expressed human COQ6 isoform A localized correctly to mitochondria when transfected into mouse podocyte cell lines, functionally validating the mitochondrial targeting/localization predicted from the protein's leader-peptide sequence.

Zebrafish model: - Morpholino knockdown of zebrafish coq6: Induced apoptosis preferentially in the head and trunk of embryos, partially rescued by co-treatment with CoQ10 (original JCI discovery paper, PMID 21540551). This in vivo functional assay was used to validate candidate variant pathogenicity identified by human homozygosity mapping — a standard approach for genes mutated in human renal-disease patients, given the zebrafish's established utility for studying podocyte biology and glomerular filtration barrier development.

Model characteristics — recapitulation and limitations: - Both the mouse-podocyte and zebrafish knockdown models recapitulate the core cellular pathology (apoptosis, oxidative stress) and, importantly, recapitulate CoQ10 treatment responsiveness, making them directly relevant translational models supporting the clinical use of CoQ10 supplementation. - Neither model is reported to recapitulate the sensorineural hearing loss or optic atrophy components of the human phenotype — the auditory and ophthalmologic aspects of disease remain modeled only indirectly (by analogy to the shared mitochondrial/oxidative-stress mechanism), which represents a translational gap: no cochlear or optic-nerve-specific Coq6 animal or cellular model was identified in this search. A curator populating a knowledge-base entry may wish to flag this using a HUMAN_MODEL_MISMATCH-type discussion, since fidelity of the podocyte models to human renal disease is well-supported (RECAPITULATES) but no equivalent auditory/ophthalmologic model exists to assess fidelity for those organ systems. - No germline mouse knockout (constitutive Coq6-null) model with a full multisystem phenotype (analogous to the human lethal infantile form) was identified in this search; existing genetic-model resources are limited to the MGI gene record (MGI:1924408) without a described knockout-phenotype allele series specific to nephrotic/deafness phenotyping.

Research applications: These models have been used specifically to (1) establish causality of candidate human COQ6 variants via functional rescue experiments, (2) dissect the oxidative-stress/apoptosis mechanism of podocyte injury, and (3) provide preclinical justification for CoQ10 supplementation as a targeted, genotype-informed therapy — directly informing the clinical treatment paradigm described in §12.

Ontology Term Summary for KB Curation

Key Citations

• Heeringa SF et al. COQ6 mutations in human patients produce nephrotic syndrome with sensorineural deafness. J Clin Invest. 2011. PMID: 21540551; JCI full text
• COQ6 mutation in patients with nephrotic syndrome, sensorineural deafness, and optic atrophy. PMID: 32685349; PMC7358665
• Effects of CoQ10 Replacement Therapy on the Audiological Characteristics of Pediatric Patients with COQ6 Variants. PMC9482153
• A Family Segregating Lethal Primary Coenzyme Q10 Deficiency Due to Two Novel COQ6 Variants. PMC8802230
• New Mutation of Coenzyme Q10 Monooxygenase 6 Causing Podocyte Injury in a Focal Segmental Glomerulosclerosis Patient. PMC6247592; DOI: 10.4103/0366-6999.245158
• CoQ10-related sustained remission of proteinuria in a child with COQ6 glomerulopathy—a case report. PMC6208703
• Primary coenzyme Q10 Deficiency-6 (COQ10D6): Two siblings with variable expressivity of the renal phenotype. ScienceDirect
• OMIM: *614647 — COQ6; #614650 — COQ10D6
• Orphanet: COQ6 gene page (ORPHA:280406)
• GeneReviews: Primary Coenzyme Q10 Deficiency Overview. NBK410087
• MedlinePlus Genetics: COQ6 gene
• Coenzyme Q Biosynthesis: Evidence for a Substrate Access Channel in the FAD-Dependent Monooxygenase Coq6. PMC4726752
• Estimating the occurrence of primary ubiquinone deficiency by analysis of large-scale sequencing data. Sci Rep. 2017. DOI: 10.1038/s41598-017-17564-y
• COQ2‐Associated Primary Coenzyme Q10 Deficiency Presenting With Proteinuria: A Case Report and Literature Review (context review discussing COQ6 modifier data). Mol Genet Genomic Med. 2026. DOI: 10.1002/mgg3.70221
• MARRVEL COQ6 gene aggregate (ClinVar variant counts): marrvel.org/human/gene/51004
• GeneCards: COQ6; MGI: Coq6 mouse gene

Reference Validation

Checked with linkml-reference-validator 0.2.1.

All extracted references resolved successfully.